Although our analyses of tumor responses and overall survival are based on very small groups and should be interpreted with the greatest caution, they could suggest that combining an mTOR inhibitor and a biguanide has anti-cancer activity in patients with advanced cancer. This evidence concerns the gene MTOR and cancer.